NEW YORK (GenomeWeb) – Quanterix said today that Tokyo-based Scrum will be the exclusive distributor of Quanterix's Simoa technology in the Japanese research market.
Lexington, Mass.-based Quanterix launched Simoa, a single-molecule array immunoassay technology for detecting and quantifying antigens and proteins, in 2013.
"We have experienced strong demand from researchers in Japan for our Simoa technology with several Japanese researcher groups traveling to Boston to access the ultrasensitive single-molecule protein detection technology in our Accelerator Lab," Quanterix CEO Kevin Hrusovsky said in a statement.
He added that Scrum would offer researchers comprehensive sales, applications, and field service support locally in Japan.
Financial and other details of the deal were not disclosed.
"Our customers have been asking about Simoa for over a year now and are very eager to have the ability to measure biomarkers with far greater sensitivity than ever before," Scrum CEO Mikio Fuchigami said.
Earlier this month, Quanterix partnered with Myriad RBM to offer immunoassay services based on the Simoa platform.